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Background: Dimethyl fumarate (DMF) is a disease-modifying drug for
relapsing-remitting multiple sclerosis. Among others, DMF impedes immune activation
by shifting the balance between inflammatory and regulatory cell types and by inducing
apoptosis-triggered lymphopenia. Although the decrease in lymphocyte count is an
early effect of the drug in several patients, the long-term impact on lymphocyte subsets
is largely unknown.
Methods: We performed a 2-years observational study on total lymphocyte count and
subsets thereof by flow cytometry of peripheral blood of 38 multiple sclerosis patients
in treatment with DMF. Data were collected at the beginning and after 3, 6, 12, and 24
months of therapy.
Results: Total lymphocyte count decreased in relation to time of exposure to DMF. Mean
absolute B cell count decreased by 34.1% (p< 0.001) within the first 3 months of therapy
and then remained stable over time. Mean absolute CD3+ T cells count decrement
reached 47.5% after 12 months of treatment (p < 0.001). NK cells count showed a
heterogeneous trend, increasing by 85.9% (p< 0.001) after 2 years of treatment. CD4+ T
cells and CD8+ T cells substantially decreased, with a significant increase of CD4+/CD8+
ratio during the first year of therapy.
Conclusions: NK cells showed a heterogeneous behavior during DMF treatment with
a significant increase over time. Since NK cells may also have a regulatory effect on
immune system modulation, their increase during DMF treatment might play a role in the
efficacy and safety of the drug.
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BACKGROUND
Dimethyl fumarate (DMF) is an approved first-line disease-
modifying treatment for relapsing remitting multiple
sclerosis (RRMS). DMF has multiple mechanisms of action
(1), including activation of the neuroprotective nuclear factor
erythroid-derived 2-related factor 2 (Nrf2) transcriptional
pathway (2) and modulation of nuclear factor kB pro-
inflammatory pathway (3). Recently, DMF and its active
metabolite monomethyl fumarate (MMF) have been shown
to target and inactivate the glycolytic enzyme glyceraldehyde
3-phosphate dehydrogenase (GAPDH) thus down-regulating
aerobic glycolysis in myeloid and lymphoid cells and preventing
immune activation (4). DMF treatment reduces the number of
distinct T and B-cell subsets, even in the absence of prolonged
and severe lymphopenia (5–9). Moreover, DMF therapy has
been observed to increase the proportion of immune-regulatory
CD56bright NK cells in the first months of treatment (10), thus
possibly influencing disease activity (11, 12).
Here we present an observational study aimed at investigating
the long-term effects of DMF on different lymphocyte subsets in
a cohort of relapsing-remitting multiple sclerosis patients.
METHODS
Patients Cohort
This 2-years observational study included 38 patients aged from
22 to 58 years (mean age 38.0 ± 8.7 years, female sex 60.5%),
with diagnosis of RRMS according to revised McDonald criteria.
Patients were recruited at the Veneto Regional Multiple Sclerosis
Center at University Hospital of Verona and were assigned to
receive DMF at standard dose. Patients were examined every 3
months during the first year of treatment and every 6 months
during the second year, with additional visits in case of relapses.
A relapse was defined as a worsening of neurological impairment
or appearance of a new symptom or abnormality attributable
to MS, lasting at least 24 h and preceded by stability of at
least 1 month (13). Expanded Disability Status Scale (EDSS)
score (14) was assessed at each visit. Intercurrent infections
were excluded by clinical and serological analyses. Twenty-five
patients were treatment naïve; 13 patients had one (6) or more
(7) previous treatments. Last treatments before introducing DMF
were interferon beta-1a (9), interferon beta-1b (1), teriflunomide
(1), glatiramer acetate (1), and cyclophosphamide (1) and were
discontinued at least 3 months before initiating DMF therapy.
Patients with no evidence of disease activity (NEDA) or with
evidence of disease activity (EDA) were also identified. NEDA
was defined as a composite score obtained from three related
measures of disease activity: (i) no evidence of relapses; (ii) no
confirmed disability progression as assessed by an increase of the
EDSS score by at least 1 point sustained over 6 months; and (iii)
Abbreviations: DMF, Dimethyl fumarate; RRMS, Relapsing Remitting Multiple
Sclerosis; NK, natural killer; Nrf2, nuclear factor erythroid 2-related factor 2;MMF,
Monomethyl fumarate; GAPDH,Glyceraldehyde 3-phosphate dehydrogenase; Th-
1, T-helper 1; Th-17, T-helper 17; Th-2, T-helper 2; T-reg, T-regulatory; EDSS,
Expanded Disability Status Scale; NEDA, No Evidence of Disease Activity; EDA,
Evidence of Disease Activity.
no new or newly enlarging white matter T2 lesions at the MRI
follow-up (15).
The Local Ethic Committee approved the present study.
Informed consent was obtained from all patients.
Flow Cytometry
Complete blood count including absolute lymphocyte counts
(ALCs) and count of total CD3+ T cells, CD19+ B cells and
CD3−CD56+ NK cells was performed by flow cytometry by
mean of ADVIA 2120i Hematology analyzer (16) at baseline
and at 3, 6, 12, and 24 months after initiating DMF therapy
(Supplementary Figure 3). Blood was processed immediately
after the collection. Data about CD8+ T cells, CD4+ T cells,
CD195+ T-helper 1 (Th-1), CD194+ T-helper 2 (Th-2), CD161+
T-helper 17 (Th-17) cells, and CD25+FOXP3+ T-regulatory (T-
reg) were also obtained in a cohort of 13 patients. ALCs were
graded in accordance with the Common Terminology Criteria
for Adverse Events (CTCAE version 4) as follows: grade 0 (≥ 910
× 109/L); grade 1 (≥800 × 109/L); grade 2 (<800–500 × 109/L);
grade 3 (<500–200× 109/L), and grade 4 (<200× 109/L).
MRI Analysis
Each patient underwent brain 3T MRI (at baseline, after 1
year and 2 years of clinical observation). MRI sequences were
acquired by Philips Achieva 3T MR Scanner (Philips Medical
Systems, Best, Netherlands). No software updating was carried
out during the study period and the scanner underwent specific
functioning test every 2 weeks to assure parameter stability and,
thus, image reproducibility and comparability. For each subject
3D T2 weighted, 3D T1 weighted Fast Field Echo (FFE) and
3D Fluid Attenuated Inversion Recovery (FLAIR) image sets
were acquired. Subjects were positioned for serial measurements
according to published guidelines for serial MRI studies in
MS (17).
Statistical Analysis
Statistical analysis was performed using Prism 7.0 (GraphPad
Software, La Jolla, CA) and R studio (Version 1.0.153); Wilcoxon
matched-pairs signed-rank test for longitudinal analysis were
applied; p < 0.05 were considered statistically significant. Linear
regression was applied to evaluate the longitudinal rate of
change in lymphocyte subsets. In the linear regression model,
for each subject time and cell counts were used, respectively,
as independent and dependent variables. Patients treated with
DMF who had a positive longitudinal trend showed a positive
β regression coefficient while patients who had a negative
trend showed a negative β regression coefficient: higher the β
coefficients, higher was the degree of increase or decrease of cell
counts. An F-test was computed on the β regression coefficients
obtained from linear regression to test the trend variability
between NK cells and the other lymphocyte subsets. Mann-
Whitney test was used to compare patients the EDA and NEDA
groups for each lymphocyte subset both at the end of the first
year of DMF treatment and at the end of the follow-up. A False
discovery rate (FDR) correction was applied.
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RESULTS
Total Lymphocyte Count
As expected, mean lymphocyte absolute count decreased during
the 2 years of treatment (see Supplementary Table 1 for detailed
absolute values at baseline and percentage changes at each
time point). After 12 months of DMF exposure 2 patients
(6.5%) developed persistent grade 3 lymphopenia, leading to
discontinuation of the treatment (Figure 1); in addition, 4
patients (12.9%) had grade 2 lymphopenia, and 2 patients (6.5%)
showed grade 1 lymphopenia. After 24 months of treatment,
1 patient (3.8%) had absolute count <500 × 109/L, while 8
patients (30.8%) had total lymphocyte count between 500 and
800 cells×109/L (Figure 1). This trend was reflected by a reduced
proportion of lymphocytes within leukocytes (not shown).
T and B Cells
The mean absolute CD3+ T cells count progressively decreased
during DMF exposure. Indeed, a 35% decrease was observed after
6 months of therapy, reaching 47.7% at the end of the second
year of treatment (Supplementary Table 1). Among CD3+ T
cells, CD8+ T lymphocytes showed a significant decrement after
1 year of treatment. In the second year the trend changed,
as shown by changes of CD4+/CD8+ ratio (Table 1). Absolute
CD8+ T cell values slightly increased during the second year
of treatment (p = 0.021 when compared to 1-year follow
up, Supplementary Figure 1) although remaining significantly
lower than baseline values (p = 0.006). CD4+ T cells showed a
downward trend, which did not reach statistical significance over
the 2 years of follow-up (p= 0.080, Table 1).
Within CD4+ T cells, Th-1 cells decrement was observed
only after 2 years of treatment (Table 1). Th-17 absolute cell
count showed a slight, but not significant, decrement after 6
months of therapy (Table 1). We then looked at other T cell
subsets, observing a different trend in Th-2 and T-reg cells.
Th-2 cell count had a slight increase after 1 year of treatment,
while, after the second year of treatment, Th-2 levels resulted
lower both when compared to baseline (p = 0.056) and one-
year follow up (p < 0.001, Supplementary Figure 1). On the
contrary, T-reg cells decreased after the first year of exposure (p
= 0.033) and then increased, reaching values similar to baseline
at the 2-years analysis (p = 0.983, Table 1). Percentage reflected
absolute mean values changes (data not shown). Absolute B cell
count showed a similar trend to CD3+ T cells; mean absolute
count showed a decrement of 34.1% after 3 months of DMF
treatment, achieving a decrement of 39.1% after 12 months (p <
0.001, Supplementary Table 1).
NK Cells
Unlike T and B cells, NK absolute count showed a strong
variability over the 2-years longitudinal observation. Indeed,
mean absolute counts increased by 85.9% after 2 years of
treatment (p < 0.001, Table 1), and the proportions of NK
cells showed an opposite trend when compared to other
lymphocyte subsets (Figure 1). However, the overall rate of such
an increase was not linear, due to marked individual variability
(Supplementary Figure 2). Regression analysis confirmed a
positive NK longitudinal trend (average β regression coefficient
of 43.1 with CV of 103) with respect to T CD3+ cells that
showed a negative trend (average T3 β regression coefficient of
−194 with CV of 73.2). This difference was statistically significant
(F-test p < 0.001).
Lymphocyte Subsets and Disease Activity
Among the 25 patients who completed the follow up, 8 showed
evidence of disease activity (EDA); all of them had a new or
FIGURE 1 | Peripheral absolute values [×109/L] of total lymphocyte count and T-cells, B-cells, and NK cells at baseline and after 3 (T3), 6 (T6), 12 (T12), and 24 (T24)
months of DMF treatment. After 2 years of treatment total lymphocyte count persisted significantly decreased (p < 0.001). B and T-cells decrement was significant
since the three months follow-up and was confirmed at the two year longitudinal analysis (p = 0.015 and p < 0.001, respectively). Conversely, NK cell count showed
a different trend, with a significant increase at the 2 years follow-up (p < 0.001).
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TABLE 1 | Absolute values [×109/L] and SD of T-cell subsets after 6, 12, and 24
months of DMF treatment compared to baseline values in a longitudinal analysis
of a smaller cohort of patients.
Baseline
(n = 13)
6 months
(n = 13)
12 months
(n = 13)
24 months
(n = 13)
CD4+ T 623.2
(212.0)
506 (245.4)
p = 0.127
522 (282.0)
p = 0.147
503.2 (282.0)
p = 0.080
CD8+ T 368.6
(337.3)
237.5(150.4)
p = 0.020
150.7 (88.0)
p = 0.002
196 (98.0)
p = 0.006
CD4+/CD8+ 2.2
(0.7)
2.4 (0.8)
p = 0.240
3.8 (1.5)
p = 0.001
2.7 (0.8)
p = 0.026
Th-1 69.8
(25.4)
102.6 (62.4)
p = 0.084
112.9 (61.5)
p = 0.034
53.9 (58.9)
p = 0.176
Th-2 64.8
(36.2)
78.5 (58.1)
p = 0.685
89.1 (36.2)
p = 0.060
38.5 (25.7)
p = 0.056
Th-17 97.5
(44.0)
76.6 (27.3)
p = 0.273
102.7 (37.6)
p = 0.772
101.5 (52.5)
p = 0.999
T-reg 14.8
(9.2)
11.9 (11.5)
p = 0.465
7.4 (4.8)
p = 0.033
14.7 (7.4)
p = 0.983
NK cells % change
3 months
% change
6 months
% change
12 months
% change
24 months
Baseline 41.2 (84.8)
n = 23,
p = 0.346
18.9 (80.5)
n = 29,
p = 0.991
75.3 (108.0)
n = 31,
p = 0.035
85.9 (98.2)
n = 26,
p < 0.001
3 months −1.9 (75.0)
n = 22,
p = 0.045
58.8 (98.2)
n = 18,
p = 0.112
50.4 (106.0)
n = 14,
p = 0.376
6 months 122 (213.0)
n = 21,
p = 0.011
101 (200.0)
n = 17,
p = 0.245
12 months 31.5 (110.0)
n = 26,
p = 0.300
NK cells absolute values at baseline and percentage change (SD) between different
time-points during DMF therapy are also shown. p < 0.05 were considered
statistically significant (bold font).
increasing white matter T2 lesion while 5 of them also suffered
a relapse.
After the two year follow up no significant differences were
detected in total lymphocyte count (p = 0.662) in B (p = 1), T
(p = 0.549) and NK cell count (p = 0.382) between the EDA and
NEDA group.
DISCUSSION
In the present study, RRMS patients assigned to receive DMF
treatment showed a significant decrease in total lymphocyte
count since the first months of treatment. However, in line
with previous studies (18, 19), a severe lymphopenia was
observed only in a very small number of patients. Nevertheless,
although opportunistic infections could happen also in patients
without substantial lymphopenia (20), the reduction of absolute
number of lymphocytes should be strictly monitored. Consistent
with the trend of the total lymphocyte population, T and B
cells showed an early and expected decrease in their absolute
values (5, 9).
In our longitudinal study a trend of preferential decrease in
CD8+ T cells was observed in the first year of therapy, but
was not confirmed in subsequent follow up; DMF mechanism
of action on T cells appears more complex than a change in
main lymphocyte subsets ratio and it probably implies a shift
of immune response throughout a more “tolerogenic” profile of
immune system (12). Such observation was partially confirmed
by the increase of T-reg cells during the second year of treatment.
Unlike T and B cell, NK cells showed a significant positive
trend. The change over time appeared quite heterogeneous,
with a consistent increase in percentage and a wide variance
in trends of absolute cell count. With the limit of simple
size, increasing percentage, and absolute count of NK cells
over time did not correlate with the degree of lymphopenia
(Supplementary Figure 2). Such increase was not detected in
previous studies (1, 21) and could reflect an increase in immune-
regulatory NK cells, particularly CD56+bright cells, which was
described in the first months of therapy (12). This change was
correlated with reduction of CD8+ memory T cells and pro-
inflammatory cytokine producing T cells (10) and has been
associated to a low activity of the disease (12), probably related
to a regulatory action on both innate and adaptive immune
system of MS patients (22, 23). Although the relationship
between CD56+bright and other NK cell subsets is not fully
understood yet (24), the mechanism by which they could regulate
central nervous system inflammation in MS patients is well
established (11).
Intriguingly, activation of NRF2 signaling pathway after DMF
therapy has been observed to increase, among the others, the
number of CD56bright natural killer cells and to be related with
the absence of disease activity after 1 year of therapy (25). In
our patient cohort no significant differences were found in total
lymphocyte count, T, B, and also NK cells in the group of patients
with disease activity compared to the NEDA group. Despite the
relatively long follow-up can partially balance such weakness,
we are aware that our conclusions are jeopardized by the
small sample size. Furthermore, the simplified characterization
of T subsets, based upon surface expression of chemokine
receptors that are not exclusively categorizable into a distinct
subset (26), might also explain some unexpected results in their
longitudinal evaluation.
Concluding, the effect of DMF on lymphocytes subsets still
needs further investigations, especially with regard to NK cells
count which appeared not in line with that of other lymphocytes.
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